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MTHFR 677C>T polymorphism genotype and allel frequencies
AF patients
with stroke
(n:70)
Control
(n:70) P
n: % n: %
CC genotype 19 27.1 37 52.9 0.002
CT genotype 27 386. 20 28. 0.210
TT genotype 24 34.3 13 18.6 0.035
CT + TT genotypes
(Dominant genetic model)
51 72.9 33 47.1 0.002
T allel 75 53.6 46 32.9 0.006
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Background: Methyleletetrahydrofolate reductase (MTHFR) gene 677C>T mutation
in the gene coding for MTHFR, characterized by the replacement of cytosine with
thymidine, leads to reduced MTHFR activity and is associated with moderately
elevated homocysteine levels. MTHFR polymorphism has been proposed by some
studies to be also a thrombophilic risk factor for venous thrombosis and athero-
thrombosis. Atrial ﬁbrillation (AF) is the commonest sustained cardiac arrhythmia,
which confers a high risk of mortality and morbidity from stroke and thromboem-
bolism. We aimed to investigate MTHFR gene 677C>T mutation in patients with AF
who have had a stroke than in healthy controls.
Methods: MTHFR gene 677C>T mutation was analysed in 70 patients with non-
valvular AF who have had a stroke and 70 healthy individuals with no documented
episode of AF matched for age, race and sex. After DNA isolation, polymorphisms
were analyze using Polymerase Chain Reaction-Restriction Fragment Length Poly-
morphism methods. Distribution of the MTHFR 677 C>T mutation alles (allel C, allel
T) and genotypes (Normal (CC) genotype, heterozygous (CT) or homozygous (TT)
mutant genotype) were identiﬁed in study population. Demographic characteristics
and risk factors for AF and stroke were evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. Genotype and allel distribution of AF patients who have had a stroke and
control groups shown in the table. The frequency of CC normal genotype of the
MTHFR gene 677 C>T was signiﬁcantly lower in patients with AF patients who have
had a stroke group compared with control group (p<0,05). The frequency of TT
homozygous mutant genotype was signiﬁcantly higher in AF patients who have had
a stroke group than control (p<0,05). Between the two groups were compared
according to the dominant genetic model (CT + TT vs. CC), The number of patients
carrying at least one T mutant allele (CT + TT) were signiﬁcantly higher in AF
patients who have had a stroke group than control (p<0,05). With respect to allelic
distribution (C vs T, additive model), the frequency of the T allele was signiﬁcantly
higher in AF patients who have had a stroke (p<0,05).
Conclusions: In this study, our data suggest that the MTHFR gene 677C>T mutation
may be associated with AF patients who have had a stroke from other clinical risk
factors, but this should be conﬁrmed in a much larger series of patients. Screening for
this mutation may help in identifying patients at risk and in deciding the antith-
rombotic strategy.C46 JACC VOP-103
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Presence of Fragmented QRS and Its Relationship with Cardiac Functions in
Patients with Obstructive Sleep Apnea
Background: Obstructive Sleep Apnea (OSA) is associated with left ventricular
dysfunction because of myocardial inﬂammation and ﬁbrosis. Fragmented QRS
(fQRS) has also been associated with myocardial ﬁbrosis and heart failure. The value
of fQRS as an indicator of myocardial ﬁbrosis and heart failure in patents with OSA
has unknown.
Objective: In this study, we aimed to assess the relationship between OSA and fQRS
with cardiac function.
Methods: One hundred eighty eight patients underwent an overnight poly-
somnography were enrolled in the study. Thirty ﬁve patients were excluded from
study according to exclusion criteria. Patients divided into two groups; group 1 had
OSA and group 2 had not. FQRS was deﬁned to be notching in R or S wave, the
presence of additional R wave (R’) or fragmented R wave (more than one R’) at least
two consecutive derivation of 12 lead electrocardiograms. Left and right cardiac
functions were assessed by myocardial performance index (Tei index) and tricuspid
annular plane systolic excursion (Tapse), respectively. Multivariable regression
analysis was performed to assess the independent relationship between fQRS and
cardiac function in patients with OSA.
Results: Group 1 consisted of 121 patients (mean age 50.510) with OSA (26 mild,
31 moderate, 64 severe) and group 2 included 32 non-OSA patients (mean age
45.349). Baseline demographic features were similar such as gender (p¼0.71),
presence of hypertension (p¼0.47), presence of diabetes (p¼0.51), the usage of b-
blocker (p¼0.91), the usage of ACE inhibitor (p¼0.53) and the body mass index
(p¼0.11). FQRS was detected in 85 (70%) of OSA patients and 4 (12.5%) of non-
OSA. Left cardiac functions were impaired in patients with OSA than non-OSA
assessed by tei index (0.6132 vs 0.43.02 p¼0.001) but right cardiac function
assessed by tapse was not impaired (24.132.6 vs 23.72.6, p¼0.56). Also, in OSA
group, patients with fQRS had impaired left cardiac functions assessed by tei index
(p<0.001) than without fQRS but right cardiac function assessed by tapse was not
impaired (p¼0.792) than those without fQRS. In multivariable logistic analyze, left
ventricular Tei index (p<0.001), lowest nocturnal oxygen saturation (p¼0.018) and
left ventricular mass index (p¼0.003) were independently associated with fQRS in
patients with OSA.
Conclusions: Patients with OSA have frequent fQRS than those without OSA.
Severity of OSA is also associated with fQRS formation. FQRS is related with
impaired left ventricular function in this population.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
Demographic properties of OSA patients
Group 1
FQRS (+)
n=89
Group 2
FQRS (-)
n=64 P-value
Age (years) 51.869.31 47.2210.60 0.018
Gender (male/female) 58/ 27 22/14 0.53
Hypertension, n(%) 30 (65.2%) 16 (34.8%) 0.41
Diabetes Mellitus, n(%) 10(58.8%) 7(41.2%) 0.26
Body mass index (kg/m2) 33.8916 31.525.9 0.39
Apnea-hypopnea index
(events/hour)
37.7928.14 25.5121.14 0.004
Lowest nocturnal oxygen
saturation (%)
66.9127.56 78.8621.14 0.025
Length of time SpO2<90%
(minute)
41.6759.6 16.240 0.021
ACE inhibitor n(%) 21(58.3%) 15(41.7%) 0.08
b-blocker n(%) 10(62.5%) 6(37.5%) 0.55
ACE: angiotensin converting enzymeEchocardiographic properties of OSA patients
FQRS (+)
n=89
FQRS (-)
n=64 P value
LVEDD (mm) 48.26 3.7 44.73.17 0<0.001
LVESD (mm) 29.62.8 26.722.67 0<0.001
EF (%) 67.93.64 69.564.23 0.031
IVS (mm) 10.70 1.06 10.31 1 0.066
PW (mm) 10.60 1.06 10  1 0.003
LV MASSINDEX (kg/m2) 92.4218.76 77.5213.43 0<0.001
LA (mm) 38.67 3.17 35.8 3 0<0.001
E (m/s) 66.313.02 76 15.33 0.007
A (m/s) 75.1715.9 7115.7 0.317
E/A ratio 0.930.32 1.120.34 0.033
Em (mm/sn) 0.10.2 0.70.3 0.109
Am (mm/sn) 0.110.2 0.100.3 0.051
Sm (mm/sn) 0.090.02 0.522.3 0.112
E/Em ratio 71.8 7.022.7 0.955
RVD (mm) 24.755.4 22.054.53 0.047
RAD (mm) 34.35.64 32.24.69 0.436
Tapse (mm) 23.662.7 23.842.56 0.792
Tei index 0.69 0.24 0.42 0.12 <0.001
A: late diastolic mitral inﬂow; A’: late diastolic mitral annular velocity; E: early diastolic mitral
inﬂow; E’: early diastolic mitral annular velocity; EF: ejection fraction; IVS: interventricular
septum; LA: left atrium; LV: left ventricle; LVEDD: left ventricular end-diastolic diameter;
LVESD: left ventricular end-systolic diameter; EF: Ejection Fraction; PW: posterior wall; S: peak
systolic mitral annular velocity; TAPSE: tricuspid annular plane systolic excursion. RAD: right
atrial minör dimension,RVD: right ventricular mid cavity diameter
Univariate correlation analysis and multivariable regression analysis for FQRS
beta P OR 95% CI P
Age 0.208 0.022 0.903 (0.823-0.991) 0.344
Apnea-hypopnea
index
0.332 <0.001 0.329 (0.073-1.483) 0.070
Lowest nocturnal
oxygen saturation
-0.374 <0.001 0.970 (0.946-0.995) 0.018
Length of time
SpO2<90%
0.339 <0.001 1.009 (0.991-1.027) 0.344
Tei index 0.526 <0.001 1.112 (1.056-1.170) <0.001
Lv mass õndex 0.400 <0.001 1.087 (1.029-1.148) 0.003
EF -0.161 0.080 0.937 (0.796-1.104) 0.437
Lv mass õndex: Left Ventricular Mass Index, EF: Ejection Fraction
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Introduction: Ivabradine, a nonselective blocker of HCN channel isoforms, as a heart
rate decreasing agent, has been validated in the therapy of coronary artery disease,
heart failure and inappropriate sinus tachycardia3. On the other hand, overexpression
of HCN channels in atrial and ventricular myocytes urged investigators to consider the
presumptive arrhythmogenic effects. However, this agent has not been validated as an
antiarrhythmic agent so far.
Case Presentation: The ﬁrst case, a 58-year old male who had coronary artery bypass
surgery 3 months ago was admitted to our hospital with palpitation of whom ECG
diagnosis was atrial ﬁbrillation. Cardioversion was attempted. However, sinus rhythm
was not restored and incessant atrial tachycardia ensued with a rate of 127 bpm
(Fig.1a). Patient was offered Ivabradine. With his approval, ivabradine was given 7.5
mg bid and on the third day changed to 22.5 mg daily. The next day tachycardia
terminated and sinusal rhythm of 60 bpm prevailed (Fig 1b). However, because of
visual side effects ivabradine was withheld and the tachycardia of 117 bpm resumed
on the very same day (Fig 1c). The day after, the rate increased to 133 bpm (Fig.1d).
So was the patient taken to EPS and single RF application ablated right atrial
tachycardia originating from coronary sinus ostium (Fig.1e).
The second case was a 60-year old male to whom metoprolol, diltiazem and sotalol
had been given to relieve symptom of palpitation for last two months. ECG diagnosis
was repetitive incessant atrial tachycardia with varying degree atrioventricular block
(Fig.2a). In the same manner ivabradine 2x7.5 mg was started. On the next day, the
atrial rhythm was slower and sinus beats were intervening (Fig.2b). Two days later
ivabradine was increased to 22.5 mg daily and the day after, slow atrial rhythm ensued
and no sinus beats were detected (Fig. 2c).
The third case, a 67-year old female with no apparent cardiac disorder, had
incessant left atrial tachycardia after failed cryoablation of pulmonary veins (PV)
(Fig.3a). Flecainide was changed to ivabradine 2x 7.5 mg and two days later the
rhythm was restored to sinus (Fig 3b).
The fourth case, a 59-year old female with hypertension and left ventricular
hypertrophy, had paroxysmal atrial ﬁbrillation while she was on amiodarone and
metoprolol (Fig.4a). The day after amiodarone was replaced with ivabradine, the
rhythm was sinusal bradycardia. Following the cessation of metoprolol the rate
increased from 45 to 61 bpm (Fig.4b-4c).
Discussion: Probably our cases are the ﬁrst to prove that ivabradine, at starting doses
which were shown as well tolerated before, can terminate sustained atrial tachyar-
rhythmias resistant to potent antiarrhythmic agents.
In conclusion, ivabradine may be a choice in drug therapy of atrial tachyarrhyth-
mias. Being effective not only on left atrial but on right atrial tachycardia as well, it
may have efﬁcacy to prevent atrial ﬁbrillation relapses.LS C47
